A clinical study included 133 people with more than 20 different subtypes of soft tissue sarcoma. They received either LARTRUVO with doxorubicin or doxorubicin alone.
The study assessed overall survival, which is how long people lived after starting treatment. The trial also measured the length of time that tumors didn’t grow, spread, or worsen after starting treatment (progression-free survival) and the proportion of people whose tumors had shrunk (objective response rate).
LARTRUVO was studied in many different subtypes. Specific clinical benefits for each subtype have not been established. Talk to your healthcare team if you have questions regarding your specific subtype. Ask your doctor if LARTRUVO + doxorubicin is right for you.
In the study, people were assigned to one of 2 groups that each received a different medication regimen:
Group 1: 66 people treated with LARTRUVO + doxorubicin (a type of chemotherapy)
Group 2: 67 people treated with doxorubicin alone
People in the study were eligible to receive treatment with anthracycline, such as the chemotherapy doxorubicin. People in the study were not eligible for curative treatment with surgery or radiation.
Select Important Safety Information
Infusion reactions related to injecting LARTRUVO have occurred. Most of these reactions happened during or after the first or second LARTRUVO infusion. Signs and symptoms of infusion reactions include flushing, shortness of breath, severe trouble breathing, or fever/chills. In severe cases, severe low blood pressure, anaphylactic shock (a severe, potentially life- threatening allergic reaction), or cardiac arrest (abrupt loss of heart function) may occur. Tell your doctor if you have any of these symptoms. Your healthcare team will monitor you for these side effects. In the case of a severe infusion reaction, your LARTRUVO treatment will have to be immediately and permanently stopped.